We rank companies based on fund manager, research analyst and news sentiment
ABIO stock icon

ARCA biopharma, Inc.


About: ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.

Employees: 5

Funds holding %
of 6,474 funds
Analysts bullish %
News positive %
of 8 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

21,400% more call options, than puts

Call options by funds: $36.6K | Put options by funds: $170

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

94% more capital invested

Capital invested by funds: $6.55M [Q3] → $12.7M (+$6.16M) [Q4]

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

29.28% more ownership

Funds ownership: 22.61% [Q3] → 51.89% (+29.28%) [Q4]

19% more funds holding

Funds holding: 21 [Q3] → 25 (+4) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for ABIO.

Financial journalist opinion

Based on 8 articles about ABIO published over the past 30 days